NEW YORK, Sept. 9 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has hired Mr. Huynho Jin to lead its business expansion in Asia.
Mr. Jin is a respected Korean business man with extensive experience in establishing and managing business operations throughout South East Asia.
"Asia is a lucrative, but often difficult-to-penetrate market due to its strong reliance on personal relationships," says Aaron Whiteman, CEO for GENova. "Mr. Jin's connections and experience in the region will be a boon for GENova. Thanks to Mr. Jin, we now have personal access to hundreds of Asian biotech startups and their promising new drug technologies."
Previously, Mr. Jin was in charge of expanding operations for Bohun Management throughout Asia. He is reputed for his management and negotiation skills, as well as his strong personal business network throughout South East Asia. Mr. Jin will grow GENova's scientific network in Asia, adding to its existing close relationships with research institutions and biotech startups in the UK, U.S., India, Spain, and Denmark.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.
Forward Looking Statements
This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.
|SOURCE GENova Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved